Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wei-Hong Zhao

Showing results (31-40 of 70) with videos related to

Pageof 7
Sort By:
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|July 25, 2007
[Clinical characteristics and prognosis of breast cancer patients with vascular invasion]Wei-Hong Zhao, Bing-He Xu, Pin Zhang, et al.
Medical Oncology (Northwood, London, England)|April 19, 2014
Standard intensive chemotherapy is less effective and far more toxic than attenuated induction and post-induction regimen in elderly patients with acute myeloid leukemiaBin-Tao Huang, Wei-Hong Zhao, Qing-Chun Zeng, et al.
Leukemia Research|February 28, 2015
Decitabine plus thalidomide yields more sustained survival rates than decitabine monotherapy for risk-tailored elderly patients with myelodysplastic syndromeWei-Hong Zhao, Qing-Chun Zeng, Bin-Tao Huang, et al.
Medical Oncology (Northwood, London, England)|September 13, 2014
A prospective, observational study of added medium-dose cytosine arabinoside versus As2O3 for elderly patients with acute promyelocytic leukemiaBin-Tao Huang, Qing-Chun Zeng, Wei-Hong Zhao, et al.
Leukemia Research|July 30, 2014
Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutationBin-Tao Huang, Qing-Chun Zeng, Wei-Hong Zhao, et al.
Medical Oncology (Northwood, London, England)|July 3, 2014
How to determine post-FCR therapy for cytogenetic risk-tailored elderly patients with chronic lymphocytic leukemia, maintenance rituximab or observationBin-Tao Huang, Qing-Chun Zeng, Wei-Hong Zhao, et al.
Medical Oncology (Northwood, London, England)|November 1, 2011
The early addition of arsenic trioxide versus high-dose arabinoside is more effective and safe as consolidation chemotherapy for risk-tailored patients with acute promyelocytic leukemia: multicenter experienceBin-Tao Huang, Qing-Chun Zeng, Arati Gurung, et al.
World Journal of Urology|September 25, 2025
Predicting postoperative fever in culture-negative patients undergoing mini-PCNL using MAP score-augmented machine learning: a retrospective cohort studyRong Xu, Jia-Jia Wang, Wei-Hong Zhao, et al.
Journal of Cancer Research and Clinical Oncology|December 17, 2013
How to determine bortezomib-based regimen for elderly patients with multiple myeloma: PAD versus CBd, an observational studyBin-Tao Huang, Yan Tan, Wei-Hong Zhao, et al.
Zhongguo Dang Dai Er Ke Za Zhi = Chinese Journal of Contemporary Pediatrics|July 13, 2017
[Adverse effects of high-dose methotrexate therapy]Qing Sun, Yao Xie, Wei-Hong Zhao, et al.
Pageof 7

Showing results (31-40 of 70) with videos related to

Sort By:
Pageof 7
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|July 25, 2007
[Clinical characteristics and prognosis of breast cancer patients with vascular invasion]Wei-Hong Zhao, Bing-He Xu, Pin Zhang, et al.
Medical Oncology (Northwood, London, England)|April 19, 2014
Standard intensive chemotherapy is less effective and far more toxic than attenuated induction and post-induction regimen in elderly patients with acute myeloid leukemiaBin-Tao Huang, Wei-Hong Zhao, Qing-Chun Zeng, et al.
Leukemia Research|February 28, 2015
Decitabine plus thalidomide yields more sustained survival rates than decitabine monotherapy for risk-tailored elderly patients with myelodysplastic syndromeWei-Hong Zhao, Qing-Chun Zeng, Bin-Tao Huang, et al.
Medical Oncology (Northwood, London, England)|September 13, 2014
A prospective, observational study of added medium-dose cytosine arabinoside versus As2O3 for elderly patients with acute promyelocytic leukemiaBin-Tao Huang, Qing-Chun Zeng, Wei-Hong Zhao, et al.
Leukemia Research|July 30, 2014
Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutationBin-Tao Huang, Qing-Chun Zeng, Wei-Hong Zhao, et al.
Medical Oncology (Northwood, London, England)|July 3, 2014
How to determine post-FCR therapy for cytogenetic risk-tailored elderly patients with chronic lymphocytic leukemia, maintenance rituximab or observationBin-Tao Huang, Qing-Chun Zeng, Wei-Hong Zhao, et al.
Medical Oncology (Northwood, London, England)|November 1, 2011
The early addition of arsenic trioxide versus high-dose arabinoside is more effective and safe as consolidation chemotherapy for risk-tailored patients with acute promyelocytic leukemia: multicenter experienceBin-Tao Huang, Qing-Chun Zeng, Arati Gurung, et al.
World Journal of Urology|September 25, 2025
Predicting postoperative fever in culture-negative patients undergoing mini-PCNL using MAP score-augmented machine learning: a retrospective cohort studyRong Xu, Jia-Jia Wang, Wei-Hong Zhao, et al.
Journal of Cancer Research and Clinical Oncology|December 17, 2013
How to determine bortezomib-based regimen for elderly patients with multiple myeloma: PAD versus CBd, an observational studyBin-Tao Huang, Yan Tan, Wei-Hong Zhao, et al.
Zhongguo Dang Dai Er Ke Za Zhi = Chinese Journal of Contemporary Pediatrics|July 13, 2017
[Adverse effects of high-dose methotrexate therapy]Qing Sun, Yao Xie, Wei-Hong Zhao, et al.
Pageof 7